Continued access to Bicycle cancer treatment
Part of Cancer clinical trials.
This trial allows people who are already doing well on a Bicycle investigational drug in another study to keep receiving that treatment. It's for patients whose disease has not gotten worse and who are tolerating the drug well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently in another Bicycle-sponsored study and are benefiting from the treatment.
- Your disease has not grown while on the treatment.
- You are tolerating the treatment without major side effects.
- You have completed all the tests required in your current study.
- You agree to use birth control during treatment and for 6.5 months after.
- You are not only receiving the drugs pembrolizumab or nivolumab for more than 24 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug for people with advanced solid tumors that have spread or can't be removed. The drug targets specific proteins on cancer cells to try to shrink or slow the cancer.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests two new drugs, P1101 and P1801, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This study lets people who were in an earlier Exelixis cancer treatment trial continue receiving the same treatment if it's still helping them. It's designed to see how safe and effective the treatment is over a longer period.
This trial lets people who were already in a related “parent” study either keep taking treatment or restart it after it had stopped working for a while. It’s meant for people who previously had a meaningful response and may still benefit from continued treatment.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.